This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fu, X. Articles by Zhang, X. Search for Related Content PubMed PubMed Citation Articles by Fu, X. Articles by Zhang, X.

Potent Systemic Antitumor Activity from an Oncolytic Herpes Simplex Virus of Syncytial Phenotype

Center for Cell and Gene Therapy [X. F., X. Z.], and Departments of Pediatrics and Molecular Virology and Microbiology [X. Z.], Baylor College of Medicine, Houston, Texas 77030

Conditionally replicating (oncolytic) viruses, which selectively replicate in tumor cells but not in normal cells, show great promise as antitumor agents for cancer therapy. The principal antitumor activity of these viruses derives from their replication within tumor cells, which results in cell destruction and the production of progeny virions that can spread to adjacent tumor cells. However, one potential limitation of this approach is that viral gene deletions conferring tumor selectivity also result frequently in reduced potency of the virus in tumors. Therefore, strategies designed to enhance the potency of current oncolytic viruses will likely increase their chance of clinical success. Here we report the construction of an oncolytic herpes simplex virus (HSV) of which the infection also causes strong cell membrane fusion (syncytial formation). In vitro characterization on a variety of human tumor cells of different tissue origins showed that the plaques from this virus (Fu-10) are phenotypically unique and are significantly larger than those from the parental G207 virus, a well-characterized oncolytic HSV lacking fusogenic function. Furthermore, the syncytial formation caused by this virus depended on HSV replication, indicating that cell membrane fusion will only occur in dividing cells (such as tumor cells) where the virus can undergo a full infection cycle but not in normal cells where the viral replication is restricted. Systemic administration of Fu-10 into mice with established lung metastatic breast cancer resulted in a dramatic therapeutic effect. These studies demonstrate that incorporation of fusogenic function into an oncolytic virus can significantly increase the potency of viral oncolysis; this may lead to an enhanced clinical performance, especially in late-stage cancer patients.

This article has been cited by other articles:

				Q. Zhang, Y. A. Yu, E. Wang, N. Chen, R. L. Danner, P. J. Munson, F. M. Marincola, and A. A. Szalay Eradication of Solid Human Breast Tumors in Nude Mice with an Intravenously Injected Light-Emitting Oncolytic Vaccinia Virus Cancer Res., October 15, 2007; 67(20): 10038 - 10046. [Abstract] [Full Text] [PDF]

				X. Fu, L. Tao, M. Li, W. E. Fisher, and X. Zhang Effective treatment of pancreatic cancer xenografts with a conditionally replicating virus derived from type 2 herpes simplex virus. Clin. Cancer Res., May 15, 2006; 12(10): 3152 - 3157. [Abstract] [Full Text] [PDF]

				M. Nakamori, X. Fu, F. Meng, A. Jin, L. Tao, R. C. Bast Jr., and X. Zhang Effective Therapy of Metastatic Ovarian Cancer with an Oncolytic Herpes Simplex Virus Incorporating Two Membrane Fusion Mechanisms Clin. Cancer Res., July 1, 2003; 9(7): 2727 - 2733. [Abstract] [Full Text] [PDF]

				J. Cinatl Jr., J. Cinatl, M. Michaelis, H. Kabickova, R. Kotchetkov, J.-U. Vogel, H. W. Doerr, T. Klingebiel, and P. H. Driever Potent Oncolytic Activity of Multimutated Herpes Simplex Virus G207 in Combination with Vincristine against Human Rhabdomyosarcoma Cancer Res., April 1, 2003; 63(7): 1508 - 1514. [Abstract] [Full Text] [PDF]